How I treat ETP-ALL in children

2.

Coustan-Smith

E

,

Mullighan

CG

,

Onciu

M

, et al.

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

.

Lancet Oncol

.

2009

;

10

(

2

):

147

-

156

.

3.

Inukai

T

,

Kiyokawa

N

,

Campana

D

, et al.

Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15

.

Br J Haematol

.

2012

;

156

(

3

):

358

-

365

.

4.

Morita

K

,

Jain

N

,

Kantarjian

H

, et al.

Outcome of T-cell acute lymphoblastic leukemia/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine

.

Am J Hematol

.

2021

;

96

(

5

):

589

-

598

.

5.

Gutierrez

A

,

Dahlberg

SE

,

Neuberg

DS

, et al.

Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia

.

J Clin Oncol

.

2010

;

28

(

24

):

3816

-

3823

.

6.

Ma

M

,

Wang

X

,

Tang

J

, et al.

Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia

.

Front Med

.

2012

;

6

(

4

):

416

-

420

.

7.

Wood

B

,

Devidas

M

,

Summers

RJ

, et al.

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group Study

.

Blood

.

2023

;

142

(

24

):

2069

-

2078

.

8.

Wood

BL

,

Winter

SS

,

Dunsmore

KP

, et al.

T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 [abstract]

.

Blood

.

2014

;

124

(

21

):

1

.

9.

Wood

BL

,

Winter

SS

,

Dunsmore

KP

, et al.

Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction—a Children's Oncology Group (COG) Study [abstract]

.

Blood

.

2009

;

114

(

22

):

9

.

10.

Loh

ML

,

Winter

SS

,

Dunsmore

KP

, et al.

Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia have high levels of minimal residual disease at the end of induction - a Children’s Oncology Group (COG) study [abstract]

.

Pediatr Blood Cancer

.

2010

;

56

(

6

):

788

.

11.

Conter

V

,

Valsecchi

MG

,

Buldini

B

, et al.

Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis

.

Lancet Haematol

.

2016

;

3

(

2

):

e80

-

e86

.

12.

Patrick

K

,

Wade

R

,

Goulden

N

, et al.

Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003

.

Br J Haematol

.

2014

;

166

(

3

):

421

-

424

.

13.

Burns

MA

,

Place

AE

,

Stevenson

KE

, et al.

Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium Protocols 05-001 and 11-001

.

Pediatr Blood Cancer

.

2021

;

68

(

1

):

e28719

.

14.

Zuurbier

L

,

Gutierrez

A

,

Mullighan

CG

, et al.

Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors

.

Haematologica

.

2014

;

99

(

1

):

94

-

102

.

15.

Dunsmore

KP

,

Winter

SS

,

Devidas

M

, et al.

Children’s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia

.

J Clin Oncol

.

2020

;

38

(

28

):

3282

-

3293

.

16.

Teachey

DT

,

Pui

C-H

.

Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia

.

Lancet Oncol

.

2019

;

20

(

3

):

e142

-

e154

.

17.

Vrooman

LM

,

Stevenson

KE

,

Supko

JG

, et al.

Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

.

J Clin Oncol

.

2013

;

31

(

9

):

1202

-

1210

.

18.

Matloub

Y

,

Stork

L

,

Asselin

B

, et al.

Outcome of children with standard-risk T-lineage acute lymphoblastic leukemia—comparison among different treatment strategies

.

Pediatr Blood Cancer

.

2016

;

63

(

2

):

255

-

261

.

19.

Winter

SS

,

Dunsmore

KP

,

Devidas

M

, et al.

Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 Methotrexate Randomization

.

J Clin Oncol

.

2018

;

36

(

29

):

2926

-

2934

.

20.

Schorin

MA

,

Blattner

S

,

Gelber

RD

, et al.

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children’s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01

.

J Clin Oncol

.

1994

;

12

(

4

):

740

-

747

.

21.

Reiter

A

,

Schrappe

M

,

Ludwig

WD

, et al.

Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86

.

Blood

.

1994

;

84

(

9

):

3122

-

3133

.

22.

Nachman

JB

,

Sather

HN

,

Sensel

MG

, et al.

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

.

N Engl J Med

.

1998

;

338

(

23

):

1663

-

1671

.

23.

Seibel

NL

,

Steinherz

PG

,

Sather

HN

, et al.

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

.

Blood

.

2008

;

111

(

5

):

2548

-

2555

.

24.

Vora

A

,

Wade

R

,

Mitchell

CD

,

Goulden

N

,

Richards

S

.

Improved outcome for children and young adults with T-cell acute lymphoblastic leukaemia (ALL): results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003 [abstract]

.

Blood

.

2008

;

112

(

11

):

908

.

25.

Vora

A

,

Goulden

N

,

Mitchell

C

, et al.

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

.

Lancet Oncol

.

2014

;

15

(

8

):

809

-

818

.

26.

Schrappe

M

,

Valsecchi

MG

,

Bartram

CR

, et al.

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

.

Blood

.

2011

;

118

(

8

):

2077

-

2084

.

27.

Delgado-Martin

C

,

Meyer

LK

,

Huang

BJ

, et al.

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias

.

Leukemia

.

2017

;

31

(

12

):

2568

-

2576

.

28.

Meyer

LK

,

Huang

BJ

,

Delgado-Martin

C

, et al.

Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes

.

J Clin Invest

.

2020

;

130

(

2

):

863

-

876

.

29.

Kawashima-Goto

S

,

Imamura

T

,

Tomoyasu

C

, et al.

BCL2 inhibitor (ABT-737): a restorer of prednisolone sensitivity in early T-cell precursor-acute lymphoblastic leukemia with high MEF2C expression?

.

PLoS One

.

2015

;

10

(

7

):

e0132926

.

30.

Follin

C

,

Erfurth

EM

.

Long-term effect of cranial radiotherapy on pituitary-hypothalamus area in childhood acute lymphoblastic leukemia survivors

.

Curr Treat Options Oncol

.

2016

;

17

(

9

):

50

.

31.

Krull

KR

,

Brinkman

TM

,

Li

C

, et al.

Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude Lifetime Cohort Study

.

J Clin Oncol

.

2013

;

31

(

35

):

4407

-

4415

.

32.

Spiegler

BJ

,

Kennedy

K

,

Maze

R

, et al.

Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate

.

J Clin Oncol

.

2006

;

24

(

24

):

3858

-

3864

.

33.

Tang

A

,

Alyman

C

,

Anderson

L

,

Hodson

DI

,

Marjerrison

S

.

Long-term social outcomes of hyperfractionated radiation on childhood ALL survivors

.

Pediatr Blood Cancer

.

2016

;

63

(

8

):

1445

-

1450

.

34.

Vilmer

E

,

Suciu

S

,

Ferster

A

, et al.

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report

.

Leukemia

.

2000

;

14

(

12

):

2257

-

2266

.

35.

Vora

A

,

Andreano

A

,

Pui

C-H

, et al.

Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy

.

J Clin Oncol

.

2016

;

34

(

9

):

919

-

926

.

36.

Pui

C-H

,

Campana

D

,

Pei

D

, et al.

Treating childhood acute lymphoblastic leukemia without cranial irradiation

.

N Engl J Med

.

2009

;

360

(

26

):

2730

-

2741

.

37.

Stark

B

,

Avrahami

G

,

Nirel

R

, et al.

Extended triple intrathecal therapy in children with T-cell acute lymphoblastic leukaemia: a report from the Israeli National ALL-Studies

.

Br J Haematol

.

2009

;

147

(

1

):

113

-

124

.

38.

Veerman

AJ

,

Kamps

WA

,

van den Berg

H

, et al.

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004)

.

Lancet Oncol

.

2009

;

10

(

10

):

957

-

966

.

39.

Teachey

DT

,

Devidas

M

,

Wood

BL

, et al.

Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma

.

J Clin Oncol

.

2022

;

40

(

19

):

2106

-

2118

.

40.

Gossai

NP

,

Devidas

M

,

Chen

Z

, et al.

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

.

Blood

.

2023

;

141

(

15

):

1802

-

1811

.

41.

O’Connor

D

,

Joy

M

,

Enshaei

A

, et al.

Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL

.

Blood Adv

.

2023

;

7

(

23

):

7231

-

7234

.

42.

Gaynon

PS

,

Steinherz

PG

,

Bleyer

WA

, et al.

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group

.

Lancet

.

1988

;

2

(

8617

):

921

-

924

.

43.

Teachey

DT

,

Hunger

SP

,

Loh

ML

.

Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia

.

Blood

.

2021

;

137

(

2

):

168

-

177

.

44.

Fowlkes

BJ

,

Edison

L

,

Mathieson

BJ

,

Chused

TM

.

Early T lymphocytes. Differentiation in vivo of adult intrathymic precursor cells

.

J Exp Med

.

1985

;

162

(

3

):

802

-

822

.

45.

Azzam

HS

,

Grinberg

A

,

Lui

K

,

Shen

H

,

Shores

EW

,

Love

PE

.

CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity

.

J Exp Med

.

1998

;

188

(

12

):

2301

-

2311

.

46.

Ferrando

AA

,

Neuberg

DS

,

Staunton

J

, et al.

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

.

Cancer Cell

.

2002

;

1

(

1

):

75

-

87

.

47.

Homminga

I

,

Pieters

R

,

Langerak

AW

, et al.

Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia

.

Cancer Cell

.

2011

;

19

(

4

):

484

-

497

.

48.

Pölönen

P

,

Elsayed

A

,

Di Giacomo

D

, et al.

Comprehensive genome characterization of childhood T-ALL links oncogene activation mechanism and subtypes to prognosis [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

1727

-

1729

.

49.

Pölönen

P

,

Elsayed

A

,

Montefiori

L

, et al.

Comprehensive genome characterization reveals new subtypes and mechanisms of oncongene deregulation in childhood T-ALL

.

HemaSphere

.

2022

;

6

(

S3

):

3

-

4

.

50.

Rheingold

SR

,

Ji

L

,

Xu

X

, et al.

Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children’s Oncology Group (COG) study

.

J Clin Oncol

.

2019

;

37

(

15

):

10008

.

51.

Raetz

EA

,

Teachey

DT

.

T-cell acute lymphoblastic leukemia

.

Hematology

.

2016

;

2016

(

1

):

580

-

588

.

52.

Petit

A

,

Trinquand

A

,

Chevret

S

, et al.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

.

Blood

.

2018

;

131

(

3

):

289

-

300

.

53.

Jenkinson

S

,

Kirkwood

AA

,

Goulden

N

,

Vora

A

,

Linch

DC

,

Gale

RE

.

Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial

.

Leukemia

.

2016

;

30

(

1

):

39

-

47

.

54.

Paganin

M

,

Grillo

MF

,

Silvestri

D

, et al.

The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols

.

Br J Haematol

.

2018

;

182

(

5

):

705

-

711

.

55.

Zhang

J

,

Ding

L

,

Holmfeldt

L

, et al.

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

.

Nature

.

2012

;

481

(

7380

):

157

-

163

.

56.

Liu

Y

,

Easton

J

,

Shao

Y

, et al.

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia

.

Nat Genet

.

2017

;

49

(

8

):

1211

-

1218

.

57.

Raetz

EA

,

Rebora

P

,

Conter

V

, et al.

Outcome for children and young adults with T-cell ALL and induction failure in contemporary trials

.

J Clin Oncol

.

2023

;

41

(

32

):

5025

-

5034

.

58.

Merli

P

,

Ifversen

M

,

Truong

TH

, et al.

Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: what level of negativity is relevant?

.

Front Pediatr

.

2021

;

9

:

777108

.

59.

Hastings

C

,

Gaynon

PS

,

Nachman

JB

, et al.

Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10⁹/l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group

.

Br J Haematol

.

2015

;

168

(

4

):

533

-

546

.

60.

Einsiedel

HG

,

Von Stackelberg

A

,

Hartmann

R

, et al.

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87

.

J Clin Oncol

.

2005

;

23

(

31

):

7942

-

7950

.

61.

Reismüller

B

,

Attarbaschi

A

,

Peters

C

, et al.

Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria – a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group

.

Br J Haematol

.

2009

;

144

(

4

):

559

-

570

.

62.

Horton

TM

,

Whitlock

JA

,

Lu

X

, et al.

Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group

.

Br J Haematol

.

2019

;

186

(

2

):

274

-

285

.

63.

Meyer

LK

,

Huang

BJ

,

Delgado-Martin

C

, et al.

Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes

.

J Clin Invest

.

2020

;

130

(

2

):

863

-

876

.

64.

Maude

SL

,

Dolai

S

,

Delgado-Martin

C

, et al.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia

.

Blood

.

2015

;

125

(

11

):

1759

-

1767

.

65.

Chonghaile

TN

,

Roderick

JE

,

Glenfield

C

, et al.

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199

.

Cancer Discov

.

2014

;

4

(

9

):

1074

-

1087

.

66.

Summers

RJ

,

Jain

J

,

Vasileiadi

E

, et al.

Therapeutic targeting of MERTK and BCL-2 in T-cell and early T-precursor acute lymphoblastic leukemia

.

Cancers (Basel)

.

2022

;

14

(

24

):

6142

.

67.

Roberts

AW

,

Seymour

JF

,

Brown

JR

, et al.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

.

J Clin Oncol

.

2012

;

30

(

5

):

488

-

496

.

68.

Wilson

WH

,

O'Connor

OA

,

Czuczman

MS

, et al.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

.

Lancet Oncol

.

2010

;

11

(

12

):

1149

-

1159

.

69.

Pullarkat

VA

,

Lacayo

NJ

,

Jabbour

E

, et al.

Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

.

Cancer Discov

.

2021

;

11

(

6

):

1440

-

1453

.

70.

Cao

H-Y

,

Chen

L-L

,

Wan

C-L

, et al.

Venetoclax combined with azacitidine was effective and safe for relapsed/refractory T-cell acute lymphoblastic leukemia/ lymphoblastic lymphoma: preliminary results of a phase 2, multicenter trial [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

1501

.

71.

Frismantas

V

,

Dobay

MP

,

Rinaldi

A

, et al.

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

.

Blood

.

2017

;

129

(

11

):

e26

-

e37

.

72.

Gocho

Y

,

Liu

J

,

Hu

J

, et al.

Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

.

Nat Cancer

.

2021

;

2

(

3

):

284

-

299

.

73.

Diorio

C

,

Teachey

DT

.

Harnessing immunotherapy for pediatric T-cell malignancies

.

Expert Rev Clin Immunol

.

2020

;

16

(

4

):

361

-

371

.

74.

Leong

S

,

Inglott

S

,

Papaleonidopoulou

F

, et al.

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy

.

Blood Adv

.

2020

;

4

(

19

):

4665

-

4668

.

75.

Bride

KL

,

Vincent

TL

,

Im

SY

, et al.

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL)

.

Blood

.

2018

;

131

(

9

):

995

-

999

.

76.

Vogiatzi

F

,

Winterberg

D

,

Lenk

L

, et al.

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

.

Blood

.

2019

;

134

(

8

):

713

-

716

.

77.

Hogan

LE

,

Bhatla

T

,

Teachey

DT

, et al.

Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): results from the phase 2 DELPHINUS study

.

J Clin Oncol

.

2022

;

40

(

16

):

10001

.

78.

Vora

A

,

Bhatla

T

,

Teachey

DT

, et al.

Efficacy and safety of daratumumab in pediatric and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma: results from phase 2 Delphinus study

.

HemaSphere

.

2022

;

6

(

S3

):

260

-

261

.

79.

Cooper

ML

,

DiPersio

JF

.

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

. 12.

Best Pract Res Clin Haematol

.

2019

;

32

(

4

):

101097

.

80.

Fleischer

LC

,

Spencer

HT

,

Raikar

SS

.

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

.

J Hematol Oncol

.

2019

;

12

(

1

):

141

.

81.

Zhao

L

,

Pan

J

,

Tang

K

, et al.

Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma

.

J Clin Oncol

.

2022

;

40

(

suppl 16

):

7035

.

82.

Pan

J

,

Tan

Y

,

Wang

G

, et al.

Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial

.

J Clin Oncol

.

2021

;

39

(

30

):

3340

-

3351

.

83.

Zhang

X

,

Yang

J

,

Li

J

, et al.

Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy

.

Am J Hematol

.

2023

;

98

(

12

):

1898

-

1908

.